m6A methylation regulators as predictors for treatment of advanced urothelial carcinoma with anti-PDL1 agent

m6A methylation regulators as predictors for treatment of advanced urothelial carcinoma with anti-PDL1 agent

PurposeImmune checkpoint blockade agents were shown to provide a survival advantage in urothelial carcinoma, while some patients got minimal benefit or side effects. Therefore, we aimed to investigate the prognostic value of m6A methylation regulators, and developed a nomogram for predicting the res...

Bibliografske podrobnosti
Main Authors:	Jianqiu Kong, Sihong Lu, Long Zhang, Yuhui Yao, Jie Zhang, Zefeng Shen, Mingli Luo, Bin Liu, Junjiong Zheng, Tianxin Lin
Format:	Article
Jezik:	English
Izdano:	Frontiers Media S.A. 2022-09-01
Serija:	Frontiers in Immunology
Teme:	m6A methylation regulators urothelial carcinoma PD1/PDL1 prediction outcome
Online dostop:	https://www.frontiersin.org/articles/10.3389/fimmu.2022.1014861/full

Podobne knjige/članki

PD-1/PDL-1 Inhibitors and Cardiotoxicity; Molecular, Etiological and Management Outlines
od: Mohammed Safi, et al.
Izdano: (2021-03-01)

Machine-Learning Guided Discovery of Bioactive Inhibitors of PD1-PDL1 Interaction
od: Sachin P. Patil, et al.
Izdano: (2022-05-01)

Multipl miyelom’da CD4+ regülatör T hücrelerin rolü
od: Deniz EKİNCİ, et al.
Izdano: (2017-09-01)

Role of PD1/PDL1 pathway, and TH17 and treg cells in maternal tolerance to the fetus
od: Sudipta Tripathi, et al.
Izdano: (2015-02-01)

Case report: Pilomatrix carcinoma with PDL1 expression and CDKN2A aberrant
od: Ayinuer Abula, et al.
Izdano: (2024-05-01)

Research Trends and Most Influential Clinical Studies on Anti-PD1/PDL1 Immunotherapy for Cancers: A Bibliometric Analysis
od: Yanhao Liu, et al.
Izdano: (2022-04-01)

Leishmania donovani: Immune response and immune evasion with emphasis on PD-1/PDL-1 pathway and role of autophagy
od: Samar Habib, et al.
Izdano: (2021-01-01)

Inactive-enriched machine-learning models exploiting patent data improve structure-based virtual screening for PDL1 dimerizers
od: Pablo Gómez-Sacristán, et al.
Izdano: (2025-01-01)

PDL1 Signals through Conserved Sequence Motifs to Overcome Interferon-Mediated Cytotoxicity
od: Maria Gato-Cañas, et al.
Izdano: (2017-08-01)

Prognostic Value of BRAF, Programmed Cell Death 1 (PD1), and PD Ligand 1 (PDL1) Protein Expression in Colon Adenocarcinoma
od: Afaf T. Ibrahiem, et al.
Izdano: (2023-01-01)

PD-L1 expression in muscle invasive urothelial carcinoma: Comparison of SP142 and SP263 assay
od: Gurudutt Gupta, et al.
Izdano: (2022-01-01)

Polymeric PD1/PDL1 bispecific antibody enhances immune checkpoint blockade therapy
od: Fuxin Xue, et al.
Izdano: (2024-10-01)

PDL1 Fusion Protein Protects Against Experimental Cerebral Malaria via Repressing Over-Reactive CD8+ T Cell Responses
od: Jun Wang, et al.
Izdano: (2019-01-01)

Adjuvant Therapy With PD1/PDL1 Inhibitors for Human Cancers: A Systematic Review and Meta-Analysis
od: Yao Jin, et al.
Izdano: (2022-02-01)

Evaluation of PDL-1 Protein Expression in Tumor Tissues of Patients with Gasteric Cancer
od: Mohammad Abbasi, et al.
Izdano: (2022-12-01)

Computational identification of PDL1 inhibitors and their cytotoxic effects with silver and gold nanoparticles
od: Syed Hammad Ali, et al.
Izdano: (2024-11-01)

Bispecific antibody simultaneously targeting AGR2 and PD1 mediates cytotoxic T-cell-induced antitumor response in AGR2-dependent manner and inhibits AGR2-induced PDL1 upregulation
od: Debmalya Roy, et al.
Izdano: (2025-02-01)

Trends in the Research Into Immune Checkpoint Blockade by Anti-PD1/PDL1 Antibodies in Cancer Immunotherapy: A Bibliometric Study
od: Yiting Sun, et al.
Izdano: (2021-08-01)

Status of PD-1 and PD-L1 expression in invasive urothelial carcinoma of the bladder with mismatch repair protein deficiency
od: Nuran Sungu, et al.
Izdano: (2023-10-01)

Programmed Cell Death Ligand 1 Expression in Circulating Tumor Cells as a Predictor of Treatment Response in Patients with Urothelial Carcinoma
od: Pei-Jhang Chiang, et al.
Izdano: (2021-07-01)

Identification of candidate genes and prognostic value analysis in patients with PDL1-positive and PDL1-negative lung adenocarcinoma
od: Xiaoguang Qi, et al.
Izdano: (2020-06-01)

Flow Cytometry-Assessed PD1/PDL1 Status in Tumor-Infiltrating Lymphocytes: A Link With the Prognosis of Diffuse Large B-Cell Lymphoma
od: Zihang Chen, et al.
Izdano: (2021-06-01)

Circ_0001946 Promotes the Development of Acute Myeloid Leukemia by Upregulating PDL1
od: Guohui Li, et al.
Izdano: (2023-08-01)

Efficacy and Safety of Anti-PD1/PDL1 in Advanced Biliary Tract Cancer: A Systematic Review and Meta-Analysis
od: Qi Jiang, et al.
Izdano: (2022-03-01)

Profile of pembrolizumab in the treatment of patients with unresectable or metastatic urothelial carcinoma
od: Inokuchi J, et al.
Izdano: (2019-05-01)

Idiopathic CD4 T Cell Lymphocytopenia: A Case of Overexpression of PD-1/PDL-1 and CTLA-4
od: Gaurav Kumar, et al.
Izdano: (2021-01-01)

The Impacts of Different Types of Radiation on the CRT and PDL1 Expression in Tumor Cells Under Normoxia and Hypoxia
od: Yangle Huang, et al.
Izdano: (2020-08-01)

Liver FOXP3 and PD1/PDL1 expression is down-regulated in chronic HBV hepatitis on maintained remission related to the degree of inflammation
od: Georgios eGermanidis, et al.
Izdano: (2013-07-01)

Maintenance immunotherapy in advanced urothelial cancer
od: María T. Bourlon, et al.
Izdano: (2022-07-01)

PDL1 expression is associated with longer postoperative, survival in adrenocortical carcinoma
od: Emilien Billon, et al.
Izdano: (2019-11-01)

Immune regulation and the tumor microenvironment in anti-PD-1/PDL-1 and anti-CTLA-4 therapies for cancer immune evasion: A bibliometric analysis
od: Yi Huang, et al.
Izdano: (2024-12-01)

Pembrolizumab plus either epacadostat or placebo for cisplatin-ineligible urothelial carcinoma: results from the ECHO-307/KEYNOTE-672 study
od: Andrea Necchi, et al.
Izdano: (2024-07-01)

Mechanisms of Resistance and Strategies to Combat Resistance in PD-(L)1 Blockade
od: John Moise, et al.
Izdano: (2022-11-01)

Investigation of the PD-1/PD-L1 Expression in the Lesional Skins of Patients with Psoriasis
od: Selma Emre, et al.
Izdano: (2023-04-01)

Expression of programmed death ligand 1 (PD-L1) in urothelial bladder carcinoma (immunohistochemical and histopathological study)
od: Nadia Ahmed Abd El-Moeze, et al.
Izdano: (2021-06-01)

Expression profiles of m6A RNA methylation regulators, PD-L1 and immune infiltrates in gastric cancer
od: Zhiyuan Xu, et al.
Izdano: (2022-08-01)

Investigation the role of SIRT3, SIRT7, NFATC1, and PDL-1 genes in androgenetic alopecia
od: Hadis Abbasian, et al.
Izdano: (2024-11-01)

Clinicopathological characteristics, molecular landscape, and biomarker landscape for predicting the efficacy of PD-1/PD-L1 inhibitors in Chinese population with mismatch repair deficient urothelial carcinoma: a real-world study
od: Yu-Ting Ma, et al.
Izdano: (2023-11-01)

Immunotherapy for the Treatment of Breast Cancer: Emerging New Data
od: Mina LA, et al.
Izdano: (2020-01-01)

Immunotherapy in the treatment of non-small cell lung cancer (NSCLC) - analysis of epidemiology and cure - review
od: Kinga Ruszel, et al.
Izdano: (2020-08-01)